Stephen Hoge, Moderna president
Moderna boasts 'step forward' with PhIII data on flu vaccine, but analysts are not so sure
The first data out of a Phase III study for Moderna’s lead flu vaccine candidate are decidedly mixed, seemingly inviting as many questions as they …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
